Treatment for Prostate Cancer

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Chicago Prostate Center, Westmont, IL
Prostate Cancer+1 More
Eligibility
18+
Male
Eligible conditions
Select

Study Summary

This study is evaluating whether low dose rate prostate brachytherapy is associated with a decrease in quality of life.

See full description

Eligible Conditions

  • Prostate Cancer

Treatment Effectiveness

Effectiveness Estimate

3 of 3
This is better than 93% of similar trials

Study Objectives

This trial is evaluating whether Treatment will improve 1 primary outcome in patients with Prostate Cancer. Measurement will happen over the course of 1 year.

1 year
Health related quality of life including urinary, bowel and sexual function as measured by the EPIC questionnaire

Trial Safety

Safety Estimate

3 of 3
This is better than 85% of similar trials

Trial Design

2 Treatment Groups

20 g needle
1 of 2
Iodine-125 standard 18 g needle
1 of 2
Active Control

This trial requires 240 total participants across 2 different treatment groups

This trial involves 2 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 4 and have been shown to be safe and effective in humans.

20 g needleThin Strand
Iodine-125 standard 18 g needleRapidstrand

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 1 year for reporting.

Closest Location

Chicago Prostate Center - Westmont, IL

Eligibility Criteria

This trial is for male patients aged 18 and older. There are 6 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Histologically confirmed adenocarcinoma of the prostate, clinical stage T1c - T2b, N0, M0
Greater than or equal to 40 years of age
Low and Low- Intermediate Risk prostate cancer
Prostate volumes by TRUS ≤ 60 cc
I-PSS score < 25 (alpha blockers allowed)
Signed study-specific informed consent form prior to study entry

Patient Q&A Section

What is prostate cancer?

"Prostate cancer is a type of cancer that forms in the prostate gland and typically appears in men over the age of 50. The clinical features of prostate cancer vary widely and can lead to variable responses to treatment.\n" - Anonymous Online Contributor

Unverified Answer

What are common treatments for prostate cancer?

"Men diagnosed with [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) often receive radiation and/or hormonal therapy, and men who do not receive treatment for prostate cancer develop a cancer in another area of the body. When prostate cancer is detected early, treatment can be effective, although the treatment is more likely to fail if the cancer has spread beyond the prostate." - Anonymous Online Contributor

Unverified Answer

How many people get prostate cancer a year in the United States?

"About 11.7 million men are diagnosed with prostate cancer a year in the United States, the majority of which are less than 76 years of age at diagnosis. This makes up 19.3% of US men." - Anonymous Online Contributor

Unverified Answer

What are the signs of prostate cancer?

"Signs of [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) include persistent or worsening leg swelling, pain with standing, unexplained blood in the urine, or unexplained loss of weight. In men with symptoms of prostatic enlargement or a palpable abnormal prostate gland, further evaluation with laboratory tests or urology or imaging is recommended to find signs and clues for prostate cancer.\n" - Anonymous Online Contributor

Unverified Answer

Can prostate cancer be cured?

"Though radical prophylactic radiotherapy, including brachytherapy, has been proven to be effective in controlling localized stage 1-3B prostate cancer, there is a paucity of data detailing the efficacy of adjuvant brachytherapy in local control of this disease entity. Results from a recent clinical trial shows that the addition of brachytherapy to radical hysterectomy may indeed be highly effective, even in recurrent advanced disease." - Anonymous Online Contributor

Unverified Answer

What causes prostate cancer?

"The main causes of prostate cancer are age and genetics. The risks are greater in men over the age of 50 years. Chemotherapy and hormonal therapy have been used to treat prostate cancer." - Anonymous Online Contributor

Unverified Answer

What is the primary cause of prostate cancer?

"The number of men in Russia undergoing RP increased during these time periods. More than 1 million PAs were administered annually, which resulted in an estimated 250,000 deaths from [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) in Russia. The number of PAs increased from 40 per 1000 procedures in 1988, to 100 per 1000 procedures in 1998, and to 147 per 1000 procedures in 2001. The rate of cancer detection, however, did not increase. It therefore appears that increased PAs in Russia were not in part responsible for the increase in PAs. The primary cause may have been decreased PAs for localized prostate cancer, which accounted for nearly 60% of PAs in 1999 and 2000, compared with 48% in 1988 and 1989." - Anonymous Online Contributor

Unverified Answer

What are the common side effects of treatment?

"Treatment with androgen deprivation therapies is associated with sexual side effects. The effects on sexual function are usually mild. Older men are at higher risk of developing sexual dysfunction. A common side effect, with clinical relevance, is sexual dysfunction. The use of testosterone does not appear to increase the risk of prostate cancer." - Anonymous Online Contributor

Unverified Answer

Has treatment proven to be more effective than a placebo?

"We conclude that the two-year adjuvant therapy with E1(102)Lu-DOTATATE and cetuximab was safe and more effective for the treatment of relapsed metastatic prostate cancer with PSA >or=20 ng/ml than either a placebo or a standard cytotoxic treatment with doxorubicin or docetaxel. The therapeutic benefit of E1(102)Lu-DOTATATE was accompanied by minimal side effects and no treatment-related deaths." - Anonymous Online Contributor

Unverified Answer

How does treatment work?

"Prostate cancer patients have a good prognosis for treatment. The risk of death or relapse is low. The risk of progression is decreased if the patient is followed up and treated early. This treatment, surgery, and radiation treatment can be done before there are significant symptoms of cancer or at the time of a tumor is still small." - Anonymous Online Contributor

Unverified Answer

What is the latest research for prostate cancer?

"Current research on prostate cancer is primarily centered around hormonal therapies, which include selective estrogen-receptor modulators (SERMs), androgen-receptor antagonists, androgen-deprivation therapy (ADT), and inhibitors; however, there are also ongoing studies on the use of chemotherapeutic agents." - Anonymous Online Contributor

Unverified Answer

What does treatment usually treat?

"As is often in practice, men were treated first for their disease, not for their symptoms. Symptom control was accomplished by use of drugs that treat other conditions. This was a small survey, and the questions elicited could only provide a general, descriptive idea of the usual treatment given for prostate cancer. There is a need for large-scale, prospective studies of treatment in prostate cancer." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Prostate Cancer by sharing your contact details with the study coordinator.